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Abstract
It is unknown whether a first influenza vaccination protects high-risk adults from severe morbidity and mortality during influenza epidemics.
As part of the PRISMA nested case–control study, we aimed to evaluate the effectiveness of first-time and repeat influenza vaccinations in























d9% of hospitalizations for acute respiratory or cardiovascular disease or death were prevented in first-time vaccinees (95% percent confidence
nterval [95% CI]: 8–90%). The corresponding figure in persons who were vaccinated before was 85% (95% CI: 36–96%). Adult persons
ith high-risk medical conditions can substantially benefit from a first and repeat influenza vaccination prior to an epidemic.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
Voordouw et al. recently showed that among elderly per-
ons a first influenza vaccination reduced the risk of mor-
ality during the influenza season only marginally, notably
n those below 70 years of age [1]. This might influence
accine uptake in elderly persons vaccinated for the first
ime in which induction of antibodies through first vacci-
ations might be sub optimal. However, this finding may
ot necessarily be applicable to younger persons who have
pecial difficulties to comply with vaccination recommenda-
ions [2]. A meta-analysis of influenza vaccine trials among
ealthy younger persons showed no differences in serolog-
cal protection rates between persons who received first or
epeat vaccinations [3]. Furthermore, it remains to be estab-
ished whether the occurrence of acute cardio-respiratory
isease requiring hospital care during influenza epidemics
∗ Corresponding author. Tel.: +31 30 253 8214; fax: +31 30 253 9028.
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can be influenced by a first vaccination. We therefore car-
ried out secondary data analysis of the Dutch Prevention of
Influenza, Surveillance and Management (PRISMA) nested
case–control study, which primarily aimed to establish the
effectiveness of influenza vaccination in preventing clinical
outcomes in influenza seasons with epidemic activity [4,5].
In this report we assessed the risk of hospitalization and mor-
tality during the 1999–2000 influenza A(H3N1) epidemic
after first and repeat influenza vaccination in adult persons
recommended for vaccination under 65 years of age [4].
2. Methods
2.1. Study design and population
Design and results of the PRISMA study have been exten-
sively described elsewhere [4–6]. In short, we conducted the
case–control study in a cohort of patients of any age eligible
for annual influenza vaccination according to Dutch primary
care immunization guidelines prior to the study season. Rec-
ommended groups for influenza vaccination included persons264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2006.01.008
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aged 65 years and older, and younger persons with a high-
risk medical condition including chronic bronchitis, emphy-
sema, asthma, and other respiratory diseases; acute or chronic
ischemic heart diseases, heart failure, atrial fibrillation, and
other heart disease; cerebrovascular disease, diabetes melli-
tus, chronic renal disease, chronic staphylococcal infection,
immune-related diseases, and patients in nursing homes and
homes for the elderly. Healthy children aged 6–24 months,
pregnant women and health care workers in general were
not recommended for vaccination. Persons with known ana-
phylactic hypersensitivity to eggs or its components have a
contra-indication for vaccination and medical records were
scrutinized to exclude such patients. During the study season,
91 practices with 75,227 study patients were included. Of this
study cohort, 33% of subjects were high-risk adults aged 18
to 64 years (n = 24,928) and for the purpose of this study we
analyzed data on cases and controls from this sub-cohort.
During the 1999–2000 influenza A(H3N2) epidemic, with
good matching of the vaccine with circulating strains, inci-
dent cases were defined as a person-period of hospitalization
because of influenza (International Classification of Primary
Care [ICPC] code [R80], pneumonia [R81]), other acute
respiratory diseases (acute bronchitis [R78], (exacerbation
of) chronic bronchitis [R91], (exacerbation of) emphysema
[R95], (exacerbation of) asthma [R96]), acute otitis media




























ratory and cardiac disease, diabetes, renal or other disease,
medication use, prior primary care visits or hospitalizations,
and specialist care using multivariate logistic regression anal-
ysis. Estimates of vaccine effectiveness (VE) and their 95%
confidence intervals (95% CI) were given in percentage as
(1-odds ratio × 100%).
3. Results
In all, the primary composite endpoint occurred in 64
persons with 70 person-periods of hospitalization or death.
Among the cases, non-fatal hospitalizations occurred in 17
cases (four pneumonia, six exacerbations of chronic pul-
monary disease, two congestive heart failure, four myocardial
infarction and one stroke), and 41 persons died in the com-
munity without prior hospitalization. In six persons, hospi-
talizations resulted in a fatal outcome (one pneumonia, four
exacerbations of chronic pulmonary disease and one myocar-
dial infarction). Influenza vaccine uptake was more than twice
as high in controls who received the vaccine before (94%)
than among those who received it for the first time (44%).
Vaccinated subjects (both first and repeat vaccinated persons)
were older and showed a higher prevalence of some high-risk
diseases than unvaccinated subjects (Table 1). Also, they were
























pre [K77] or stroke [K90], or death from any cause. For the
otential cases that had a general practitioner (GP) refer-
al to hospital that was labeled as an exacerbation of the
sthma/COPD, we scrutinized all medical records to see
hether a prescription for oral corticosteroı¨ds was given.
hese additional eligibility criteria were developed to ascer-
ain acute onset of the chronic diseases. For each possible
ase identified by a computerized search on ICPC-codes in
pril–May after the study season, four control persons with-
ut an endpoint were randomly selected by computer from
he remainder of that season’s base-line cohort. Sampling of
ontrols was conducted within the same age-subgroup as the
ase and during the same season.
.2. Endpoints and statistical analysis
The primary endpoint was a composite of hospital admis-
ion for acute respiratory or cardiovascular disease, or death
rom any cause, and secondary endpoints were the separate
omponents hospitalization or death. Cases could experience
hospital admission or could die from any cause. Those cases
hat subsequently experienced both outcomes were counted
s a person-period for both separate endpoints and as a first
erson-period for the combined endpoint. We derived esti-
ates of vaccine effectiveness in reducing these endpoints for
ersons who received the influenza vaccination for the first
ime and for those who received the vaccine also in the season
rior to the 1999–2000 influenza season (1998). We further
djusted effect estimates for potential confounders including
ge, gender, health care insurance status, history of respi-NHI), indicating a lower social economic status. Moreover,
hese subjects received more hospital care. Characteristics of
ersons who received the vaccine for the first time were not
uch different from those who received the vaccine repeat
imes, except for specialist care in the previous 12 months.
After adjustments, a first influenza vaccination was asso-
iated with substantial reductions in the primary and sec-
ndary endpoints (Table 2). Point estimate of vaccine effec-
iveness estimates were not substantially different from the
ohort of persons who received repeat vaccinations and dif-
erences were statistically non-significant (p-value for inter-
ction > 0.05).
. Discussion
These data on a younger age-cohort complement those
rom Voordouw et al. [1] and showed that in contrast to their
ndings among elderly persons, first vaccinations in younger
igh-risk adults were associated with significant benefits.
lthough our study lacked statistical power to make conclu-
ions about benefits regarding hospitalizations with repeat
accinations in high-risk younger adults, the point estimates
howed substantial reductions. Importantly, the risk of mor-
ality was substantially lower among high-risk adults who
eceived repeat vaccinations.
To appreciate these findings some issues need to be con-
idered. The used case–control approach enables the assess-
ents of the effects of vaccination on infrequent severe end-
oints such as hospitalization or death [4]. The distribution
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Table 1
Base-line characteristics estimated from controls for the group of high-risk adults
Characteristic Unvaccinated N = 532 First vaccination N = 379 p-value* Repeat vaccinations N = 867 p-value**
Mean age (S.D.) 42 (14) 49 (12) <0.001 48 (14) <0.001
Male sex 254 (48) 170 (45) 0.392 399 (46) 0.532
NHI 339 (64) 266 (70) 0.041 612 (71) 0.008
Asthma/COPD 288 (54) 174 (46) 0.014 406 (47) 0.007
Heart disease 74 (18) 88 (23) 0.039 211 (24) 0.003
Diabetes mellitus 57 (11) 68 (18) 0.002 180 (21) <0.001
Other diseasea 121 (23) 75 (20) 0.285 161 (19) 0.059
Mean no. of GP visitsb 0.3 (1.3) 0.4 (1.4) 0.753 0.7 (2) 0.001
Mean no. of prescriptionsb 0.5 (1.0) 0.4 (1.0) 0.085 0.8 (1.3) <0.001
Specialist careb 41 (8) 26 (7) 0.634 140 (16) <0.001
Hospitalizationb 5 (1) 9 (2) 0.083 17 (2) 0.134
NHI: National Health Insurance; GP: general practitioner.
a Other disease: renal disease, immune-related disease.
b In previous 12 months.
* p-value comparing persons who received vaccine for the first time with unvaccinated persons.
** p-value comparing persons who received vaccine for the second time or more with unvaccinated persons.
Table 2
Effect of first and repeat influenza vaccination (VE in %) in reducing hospitalization and mortality among adult high-risk persons 18–65 years of age during
the 1999–2000 influenza A epidemic
Subgroups Composite endpoint Hospitalization for ARD or CVD Death from any cause
First vaccination in high-risk persons 18–64 years
No. vaccinated cases/total no. cases (%) 9/31 (29) 1/8 (13) 8/27 (30)
No. vaccinated controls/total no. controls (%) 379/853 (44) 379/853 (44) 379/853 (44)
Unadjusted vaccine effectiveness (95% CI) 49 (−13; 77) 82 (−46; 98) 47 (−22; 77)
Adjusted vaccine effectiveness (95% CI) 69 (8; 90) 97 (13; 99) 65 (−10; 89)
Adjusted p-value 0.036 0.040 0.073
Repeat vaccination in high-risk persons 18–64 years
No. vaccinated cases/total no. cases (%) 26/33 (79) 13/15 (87) 14/20 (70)
No. vaccinated controls/total no. controls (%) 867/925 (94) 867/925 (94) 867/925 (94)
Unadjusted vaccine effectiveness (95% CI) 75 (40; 90) 56 (−97; 93) 84 (58; 94)
Adjusted vaccine effectiveness (95% CI) 85 (36; 96) 71 (−330; 97) 92 (48; 99)
Adjusted p-value 0.010 0.370 0.008
Statistical interaction first vs. repeat vaccinations in
high-risk persons 18–64 years ( p-value)
0.433 0.306 0.132
Abbreviations: ARD—influenza, pneumonia, acute bronchitis, exacerbation of chronic pulmonary disease; CVD—acute myocardial infarction, congestive
heart failure; high-risk: with chronic medical conditions with an indication for influenza vaccination (see Section 2).
of some important characteristics in vaccinated and unvac-
cinated controls was similar to figures observed in earlier
vaccination studies and not substantially different between
persons who received the vaccine for the first time or mul-
tiple times. Furthermore, the potential for recall bias was
minimized through the complete review of prospectively
collected data in routine medical care from computerized
medical records.
A major issue in non-experimental evaluation of vaccines
is that by definition, patients are selected by their general
practitioner or by themselves to be vaccinated which may
lead to confounding bias [7]. As also shown by Voordouw et
al.’s study [1], the presence of risk factors is higher among
vaccinated than unvaccinated persons which may have influ-
enced observed associations. However, we minimized this
so-called ‘confounding by indication’ in both the design
and data-analysis phases of the study [7]. First, we only
admitted patients with current indications for vaccination as
verified by the GP into the study cohort. Second, since age
and presence of high-risk disease are major confounders, we
frequency-matched cases and controls on these factors by
sampling in subgroups and controlled for their confounding
effect in the analyses. Third, we had information on many
additional potential confounders and adjusted for these using
logistic regression analysis. Obviously, only a large enough
randomized controlled trial will fully guarantee absence of
confounding, but it is very unlikely that the observed vaccine
effectiveness estimates are materially influenced by residual
confounding. If so, the reported estimations can only be val-
ued as underestimations since in general vaccinated persons
run a higher risk for developing an endpoint than unvacci-
nated persons as shown in Table 1.
The number of mean GP visits and medical drug prescrip-
tions were rather low. There may be two explanations for this:
first, about 8% of the patient population is under treatment by
a specialist and therefore visits and medications in primary
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care are limited for these persons. Second, the high-risk dis-
eases (mostly asthma) in many adult patients in primary care
have a rather mild course that either does not need chronic
treatment or regular GP visits.
Finally, we had information on exposure to influenza vac-
cination for only two influenza seasons and therefore could
not analyze potential differences for those persons who inter-
rupted vaccinations. In Beyer’s study, such an effect was also
not studied and it remains to be established whether such an
interruption influences the effects of vaccination. Obviously,
the vaccine can only be protective against severe and infre-
quent clinical outcomes when influenza activity is high and
the vaccine matches the seasonal viral strains [8]. More stud-
ies are needed to determine the long-term effectiveness and
cost-effectiveness of such a vaccination program.
Among the main determinants of compliance with vaccine
recommendations is the perception of benefit from the vac-
cine and health care workers should not miss the opportunity
to educate younger high-risk patients about the significant
benefits of vaccination.
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